Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 7, 2022; 10(1): 260-267
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.260
HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen
Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen, Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Author contributions: Wang L and Jiang Q contributed equally to this work; all authors have read and approved the final manuscript.
Informed consent statement: The participant in this study provided written informed consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there are no any conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Peng Shen, MD, Doctor, Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. shenp@zju.edu.cn
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: June 7, 2021
Revised: June 10, 2021
Accepted: July 12, 2021
Article in press: July 12, 2021
Published online: January 7, 2022
Processing time: 304 Days and 19.9 Hours
Core Tip

Core Tip: The precise molecular subtype of breast cancer is helpful in order to develop individualized strategies for systemic treatment; thus, more attention should be paid to the changes in tumor biomarkers before and after surgery. The conversion probability is fairly low, especially regarding HER2 status; however, it directly affects the formulation of adjuvant treatment. Importantly, anti-HER2 therapy has led to a landmark change in patients with HER2 positive breast cancer.